ICIs activate the immune response within the immunosuppressive tumor microenvironment of BM [9] by targeting specific proteins on the surface of cancer cells (PD-L1) or immune cells (PD-1), maintaining a normal immune response (Figure 1). The gene discussed is CD274; the disease is neoplasm.